On January 21, 2026, the U.S. Food and Drug Administration designated Eli Lilly’s investigational agent, sof etabart mipitecan, as a Breakthrough Therapy. This designation applies to patients with platinum-resistant ovarian cancer who have progressed after at least two prior lines of therapy. The FDA cited early clinical data showing an objective response rate of 28% in heavily pretreated patients and a median progression-free survival of 4.5 months, compared with historical controls of approximately 2 months. The Breakthrough Therapy status will allow Lilly to engage in more frequent interactions with the agency, potentially accelerating the path to a Biologics License Application and priority review.

Eli Lilly announced it will release fourth-quarter 2025 financial results on February 4, 2026, followed by a live conference call at 10:00 a.m. Eastern Time. The webcast link will be available on Lilly’s investor website, with a replay following the event. This is Lilly’s first quarterly report since securing FDA approval for its Alzheimer’s candidate in late 2025 and ahead of initial U.S. launch volumes for its once-weekly GLP-1 obesity therapy, Zepbound. Analysts expect management commentary to address manufacturing scale-up for Zepbound, margin outlook given increased R&D investment, and guidance for full-year 2026 revenue growth in the mid-teens percentage range.

Lilly remains the global leader in GLP-1 therapies, with Mounjaro and Zepbound generating combined annualized prescriptions exceeding 2 million as of December 2025. Market research firm BioTrends projects GLP-1 revenues to grow at a compound annual rate of 30% through 2028, driven by an anticipated U.S. oral obesity therapy launch in Q2 2026. Management has guided for supply to meet 80% of demand by mid-year, following recent capacity expansions at its manufacturing facility in Indiana. At the same time, Lilly is investing over $1.2 billion in late-stage trials across Alzheimer’s, cardiovascular disease and oncology, reinforcing a diversified pipeline that supports continued top-line momentum.